0001654954-20-007013.txt : 20200626 0001654954-20-007013.hdr.sgml : 20200626 20200626170027 ACCESSION NUMBER: 0001654954-20-007013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200624 FILED AS OF DATE: 20200626 DATE AS OF CHANGE: 20200626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WILLS STEPHEN T CENTRAL INDEX KEY: 0001103883 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15543 FILM NUMBER: 20994850 MAIL ADDRESS: STREET 1: PALATIN TECHNOLOGIES, INC. STREET 2: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC CENTRAL INDEX KEY: 0000911216 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954078884 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: 609-495-2200 MAIL ADDRESS: STREET 1: 4B CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FORMER COMPANY: FORMER CONFORMED NAME: INTERFILM INC DATE OF NAME CHANGE: 19930825 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2020-06-24 0000911216 PALATIN TECHNOLOGIES INC PTN 0001103883 WILLS STEPHEN T PALATIN TECHNOLOGIES, INC. 4B CEDAR BROOK DRIVE CRANBURY NJ 08512 false true false false Executive VP and CFO/COO Common Stock 2020-06-25 4 A false 278500 0 A 6291489 D Common Stock 2020-06-24 4 A false 42925 0 A 6334414 D Stock Option (Right to Buy) 0.58 2020-06-25 4 A false 461500 0 A 2021-06-16 2030-06-16 Common Stock 461500 461500 D Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 16, 2021. Restricted share units were granted June 16, 2020, contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved by the stockholders at a meeting on June 25, 2020. Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 24, 2020, upon certification by the Compensation Committee that a defined performance objective as to 85% of the target number of share units for the fiscal year ending June 30, 2020 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in licensing of Vyleesi in additional countries or regions. The options vest at the rate of 25% per year, starting on June 16, 2021. Options were granted June 16, 2020, contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved by the stockholders at a meeting on June 25, 2020. /s/ Stephen T. Wills, by Stephen A. Slusher, Attorney-In-Fact 2020-06-26